Evaluating Prostate Cancer Bone Metastases Response with Whole-body MRI: What We Know and Still Need to Know

Overview

Journal Eur Radiol

Specialty Radiology

Date 2024 Jun 20

PMID 38902565

Authors

Anwar R Padhani

Nina Tunariu

Raquel Perez-Lopez

Betrand Tombal

Frederic E Lecouvet

Affiliations

Soon will be listed here.

References

Gillessen S, Omlin A, Attard G, de Bono J, Efstathiou E, Fizazi K . Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol. 2016; 30(12):e3. DOI: 10.1093/annonc/mdw180. View

Batra A, Glick D, Valdes M . Contemporary Systemic Therapy Intensification for Prostate Cancer: A Review for General Practitioners in Oncology. Curr Oncol. 2024; 31(2):1047-1062. PMC: 10888029. DOI: 10.3390/curroncol31020078. View

Quintanal-Villalonga A, Chan J, Yu H, Peer D, Sawyers C, Sen T . Lineage plasticity in cancer: a shared pathway of therapeutic resistance. Nat Rev Clin Oncol. 2020; 17(6):360-371. PMC: 7397755. DOI: 10.1038/s41571-020-0340-z. View

Bryce A, Chen Y, Liu G, Carducci M, Jarrard D, Garcia J . Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. Eur Urol Oncol. 2020; 3(6):717-724. PMC: 7738423. DOI: 10.1016/j.euo.2020.07.001. View

Robbrecht D, Delanoy N, Tannock I, Tombal B, Eisenberger M, Fizazi K . Impact of progression at baseline and on-treatment progression events in three large prostate cancer trials. Eur J Cancer. 2019; 125:142-152. DOI: 10.1016/j.ejca.2019.10.029. View

Bryce A, Alumkal J, Armstrong A, Higano C, Iversen P, Sternberg C . Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017; 20(2):221-227. PMC: 5435962. DOI: 10.1038/pcan.2016.71. View

Schaeffer E, Srinivas S, Adra N, An Y, Barocas D, Bitting R . Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023; 21(10):1067-1096. DOI: 10.6004/jnccn.2023.0050. View

Perez-Lopez R, Tunariu N, Padhani A, Oyen W, Fanti S, Vargas H . Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. Radiology. 2019; 292(2):273-286. DOI: 10.1148/radiol.2019181931. View

Padhani A, Lecouvet F, Tunariu N, Koh D, De Keyzer F, Collins D . METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer. Eur Urol. 2016; 71(1):81-92. PMC: 5176005. DOI: 10.1016/j.eururo.2016.05.033. View

10.

Trabulsi E, Rumble R, Jadvar H, Hope T, Pomper M, Turkbey B . Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020; 38(17):1963-1996. DOI: 10.1200/JCO.19.02757. View

11.

Donners R, Figueiredo I, Tunariu N, Blackledge M, Koh D, Fenor de La Maza M . Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing. Eur Radiol. 2022; 32(7):4647-4656. PMC: 9213271. DOI: 10.1007/s00330-022-08536-6. View

12.

Donners R, Figueiredo I, Westaby D, Koh D, Tunariu N, Carreira S . Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer. Cancer Imaging. 2023; 23(1):121. PMC: 10724964. DOI: 10.1186/s40644-023-00644-w. View

13.

Pricolo P, Ancona E, Summers P, Abreu-Gomez J, Alessi S, Jereczek-Fossa B . Whole-body magnetic resonance imaging (WB-MRI) reporting with the METastasis Reporting and Data System for Prostate Cancer (MET-RADS-P): inter-observer agreement between readers of different expertise levels. Cancer Imaging. 2020; 20(1):77. PMC: 7590732. DOI: 10.1186/s40644-020-00350-x. View

14.

Belotti A, Ribolla R, Crippa C, Chiarini M, Giustini V, Ferrari S . Predictive role of sustained imaging MRD negativity assessed by diffusion-weighted whole-body MRI in multiple myeloma. Am J Hematol. 2023; 98(9):E230-E232. DOI: 10.1002/ajh.26995. View

15.

Kosmin M, Padhani A, Gogbashian A, Woolf D, Ah-See M, Ostler P . Comparison of Whole-Body MRI, CT, and Bone Scintigraphy for Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to Bone. Radiology. 2020; 297(3):622-629. DOI: 10.1148/radiol.2020192683. View